Breaking: Jobs boost for Kildare as Pfizer announces Newbridge investment

Pfizer investment to bring 300 new jobs to Ireland over two to three years

Henry Bauress


Henry Bauress


Pharma jobs boost for Kildare

More jobs for Newbridge plant


Kildare will have an approximate even share of 300 new jobs being announced by Pfizer today.

The jobs will be created over the next two to three years and will bring to 4,000 the company staff in Ireland.

The pharmaceutical company is announcing approximately €300 million capital investment in its Irish operations which, it said, will support the further development of existing manufacturing sites in Newbridge, Grange Castle  and Ringaskiddy.

A company spokesperson told us this morning the new jobs would be spread roughly evenly over the three Irish sites.

Paul Reid, Country Manager, Pfizer Healthcare Ireland, said: “Currently we are focused on our COVID-19 efforts, including our vaccine development program. Pfizer is also significantly investing in other innovations across healthcare – such as gene therapy and complex biologics targeting some of the most debilitating medical conditions.”

Pfiizer said the investment will provide additional manufacturing and laboratory capacity creating approximately 300 roles, with additional anticipated construction roles in Ringaskiddy, Cork.

  The investment and additional roles will be completed over the next two to three years.

Dr. Paul Duffy, Vice President, Pfizer Global Supply said: “Pharmaceutical manufacturing in Ireland continues to perform very well contributing strongly to exports and economic growth and provides excellent career opportunities. Pfizer has an extensive global and U.S. footprint with operations in over 125 countries worldwide and we are very pleased with today’s announcements which will strengthen our Irish operations and bring our total headcount in Ireland to 4,000.  It is also particularly exciting that our Ringaskiddy site has been chosen as the location to manufacture investigational compounds for our clinical trials globally and we look forward to seeing that new facility become operational.”

 The company said: “The investment and roles being created will upgrade and enhance existing facilities, expand manufacturing and laboratory capacity and add new technologies to ensure Pfizer is ready to support the next wave of medical innovations. Part of the investment includes the initial stage of a project to construct a development facility on the existing Ringaskiddy site to manufacture pharmaceutical compounds for Pfizer’s clinical trials globally. This is a very important development as it expands Pfizer’s role in Ireland from the manufacture of already approved medicines into supporting the earlier phases of new medicine development.”

 The company said Irish sites manufacture leading medicines and vaccines in the areas of arthritis, inflammation, cancer, anti-infectives, haemophilia, pain and stroke. The roles being recruited for comprise a broad range of highly skilled roles including; analysts, technicians, engineers, scientists, technologists, quality specialists, data analysts and chemists.

 An Taoiseach, Micheál Martin, said: “This significant jobs and investment announcement by Pfizer is a further vote of confidence in the skills and talent of Irish people and provides a very welcome boost to the economy.”

Martin Shanahan, CEO, IDA Ireland, said: “Pfizer is one of Ireland’s largest pharmaceutical investors. This investment announcement and the substantial number of additional highly skilled roles across its three Irish sites is a huge vote of confidence in Ireland’s investment environment and again underscores Ireland’s reputation as a global location of excellence for biopharmaceuticals.  I wish the Pfizer team continued success with this expansion.”

Details of all roles are available on